Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
Completed · Phase 3 · NCT04167514
Conditions: Graft Versus Host Disease (GVHD)
At a glance
- Research payments reported, 2025
- $138,266
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 136
About the trial
- Sponsor
- CSL Behring (with Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI))
- Tested
- Alpha-1 antitrypsin (AAT) (biological), Placebo (drug)
- Dates
- Started 2020-01-09; completion 2024-06-26
- Results posted
- Yes
Study CSL964\_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD
From ClinicalTrials.gov, last updated 2026-07-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $138,266 in research payments for this study in 2025 (1 payments).
Products named: Zemaira
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.